Related Experiment Videos
Dialysis-associated amyloidosis
T Drüeke1, M Touam, J Zingraff
1INSERM Unité 90, Hôpital Necker, Paris, France.
Advances in Renal Replacement Therapy
|January 1, 1995
Summary
Dialysis-related arthropathy is linked to beta-2 microglobulin (beta 2-M) amyloidosis. Advances in dialysis technology may reduce this complication by improving beta 2-M removal and biocompatibility.
Area of Science:
- Nephrology
- Rheumatology
- Biochemistry
Background:
- Dialysis-related arthropathy is a significant complication in patients undergoing renal replacement therapy.
- This condition is associated with beta-2 microglobulin (beta 2-M) amyloidosis.
Purpose of the Study:
- To explore the pathogenesis of dialysis-related arthropathy.
- To investigate the role of beta-2 microglobulin (beta 2-M) and potential contributing factors.
Main Methods:
- Review of existing literature on beta-2 microglobulin (beta 2-M) amyloidosis and dialysis complications.
- Analysis of factors influencing beta-2 microglobulin (beta 2-M) metabolism and deposition.
Main Results:
- Chronic renal failure leads to beta-2 microglobulin (beta 2-M) retention, a prerequisite for amyloidosis.
- Inflammatory mediators, altered beta 2-M metabolism, and dialysis membrane biocompatibility may also contribute to pathogenesis.
- Modern dialysis techniques, including high-flux dialyzers, can enhance beta 2-M removal and reduce procedure bioincompatibility.
Conclusions:
- While beta-2 microglobulin (beta 2-M) retention is key, other factors are involved in dialysis-related arthropathy.
- Technical advancements in dialysis may decrease the incidence of symptomatic beta 2-M amyloidosis.